Would not surprise me - the sales cycle in Enterprise Health is notoriously long (as evidenced by any lack of current revenues in Australia despite TGA approval a long while ago) and any FDA clearance if granted (which is not FDA approval which is entirely different) is just the first step to commercialisation in the US. This will be a slow burner IMHO.
- Forums
- ASX - By Stock
- AYA
- Ann: Quarterly Activities/Appendix 4C Cash Flow Report
Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-5
Featured News
Add AYA (ASX) to my watchlist
(20min delay)
|
|||||
Last
25.5¢ |
Change
0.005(2.00%) |
Mkt cap ! $19.67M |
Open | High | Low | Value | Volume |
25.5¢ | 25.5¢ | 25.5¢ | $757 | 2.967K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 48420 | 25.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
25.5¢ | 3993 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 48420 | 0.250 |
1 | 41666 | 0.240 |
1 | 50000 | 0.230 |
1 | 4900 | 0.225 |
2 | 6500 | 0.220 |
Price($) | Vol. | No. |
---|---|---|
0.255 | 3993 | 1 |
0.260 | 12665 | 1 |
0.265 | 23150 | 2 |
0.300 | 7404 | 1 |
0.315 | 3501 | 1 |
Last trade - 14.21pm 27/09/2024 (20 minute delay) ? |
Featured News
AYA (ASX) Chart |